“One of the Most Painful Years of My Life” – Psychedelic Leader Opens Up About the Battle for MDMA Therapy

“One of the Most Painful Years of My Life” – Psychedelic Leader Opens Up About the Battle for MDMA Therapy

Dil Bar Irshad | February 22, 2025 | 06:08 PM IST | World | Follow on Google News

“One of the Most Painful Years of My Life” – Psychedelic Leader Opens Up About the Battle for MDMA Therapy

February 2025 – In an unfiltered and deeply personal conversation on the Love You Wealth podcast, Rick Doblin, founder of MAPS (Multidisciplinary Association for Psychedelic Studies), revealed the agonizing challenges behind the push to legalize MDMA-assisted therapy—a battle that has left him grappling with one of the hardest years of his life.

Doblin, who has spent over four decades advocating for psychedelic medicine, spoke openly about the FDA’s rejection of MDMA-assisted therapy, the tensions between corporate and grassroots psychedelic movements, and the loss of focus on public benefit in the for-profit sector.

“They Wanted to Be a Drug Company, Not a Therapy Company”

With MAPS’ for-profit arm, Lykos, created to commercialize MDMA-assisted therapy, Doblin expected to see the mission of public benefit continue. Instead, he saw a painful shift toward traditional pharmaceutical strategies—leaving behind the very therapy that made MDMA effective.

Read More Here.

“We had to move forward with investors, and even though they were impact investors, what I found is that the incentive structure had changed. People started focusing more on financial returns than public benefit.” – Rick Doblin

“They wanted to be a drug company, NOT a therapy company.”

The Psychedelic Seesaw: A Movement at a Crossroads

For Cesar Marin, host of Love You Wealth and founder of Cultivating Wisdom, this tension is something he sees playing out across the entire psychedelic landscape.

“Psychedelics are on a seesaw. On one side, you have the corporate world—Compass Pathways, patents, FDA approvals. On the other side, you have the grassroots, the culture, the people saying, ‘Are you crazy? I grow my own mushrooms.’ And Rick stands right in the middle of that seesaw, trying to balance it.” – Cesar Marin

Marin believes this divide must be bridged—not ignored—if psychedelics are going to make it into mainstream medicine without losing their soul.

The FDA Battle: Inside the Fight for Legitimacy

For co-host Gary Seelhorst, a former pharmaceutical executive and psychedelic drug researcher, the challenge of bringing MDMA through FDA approval was always going to be an uphill battle.

“The FDA has never approved a combination treatment like MDMA-assisted therapy. They’re used to approving pills—not an entire therapeutic process. And when you’re trying to get a regulator to think in a completely new way, that’s no small task.” – Gary Seelhorst

Doblin echoed that frustration, revealing how Lykos’ decision to remain silent before the FDA decision cost them control of the narrative.

“Traditional pharma companies have what they call a quiet period before FDA approval. But MDMA isn’t just another drug—it’s one of the most well-known recreational substances in the world. When you go silent, you lose control of the narrative. And that’s exactly what happened.”

Reclaiming the Mission: The Future of Psychedelic Medicine

Despite the setbacks, Doblin remains relentless in his pursuit to make MDMA therapy accessible and affordable for those who need it most. But he warns that this movement must be intentional about where it’s heading.

“We need to build bridges, not burn them. But if you want to be a bridge, you have to get used to being stepped on.”

For Marin, Seelhorst, and Doblin, the future of psychedelic medicine hinges on a delicate balance—ensuring that science, accessibility, and ethics remain at the forefront.

Watch the full episode now on YouTube, LinkedIn, Facebook, and Spotify.

Dil Bar Irshad

Dil Bar Irshad is a seasoned journalist, hails from Jammu Kashmir's Doda, covers political, social, business stories, index stories.